Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery

Advanced Drug Delivery Reviews

Volumn 27, Issue 2-3, 1997, Pages 201-214

  Hebert, M F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CYP3A4; CYP3A5; Drug interactions; mdr1; Review

Indexed keywords

DRUG INTERACTIONS; DRUG THERAPY; ENZYMES; METABOLISM; PROTEINS; SUBSTRATES;

CYCLOSPORINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ORAL DRUG DELIVERY; P GLYCOPROTEIN; TACROLIMUS;

PHARMACOKINETICS;

AMIODARONE; CARBAMAZEPINE; CLARITHROMYCIN; CLOTRIMAZOLE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DANAZOL; DEXAMETHASONE; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; GLYCOPROTEIN P; ITRACONAZOLE; KETOCONAZOLE; METHYLPREDNISOLONE; METOCLOPRAMIDE; NICARDIPINE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SULFONAMIDE; TACROLIMUS; TRIMETHOPRIM; TROLEANDOMYCIN; VERAPAMIL;

DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; FOOD DRUG INTERACTION; HUMAN; INTESTINE ABSORPTION; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; REVIEW;

EID: 0343416856     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00043-4     Document Type: Review

References (131)

1. Wu C.Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., Wacher V.J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58:1995;492-497.
2. Hebert M.F., Roberts J.P., Prueksaritanont T., Benet L.Z. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52:1992;453-457.
3. Floren L.C., Bekersky I., Benet L.Z., Mekki Q., Dressler D., Lee J.W., Roberts J.P., Hebert M.F. The effects of ketoconazole on the pharmacokinetic disposition of tacrolimus. Pharm. Res. 13:1996;S-411.
4. Kleinbloesem C.H., vam Brummelen P., Faber H., Danhof M., Vermeulen N.P.E., Breimer D.D. Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man. Biochem. Pharmacol. 33:1984;3721-3724.
5. Schellens J.H.M., Soons P.A., Breimer D.D. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem. Pharmacol. 37:1988;2507-2510.
6. Watkins P.B., Wrighton S.A., Schuetz E.G., Molowa D.T., Guzelian P.S. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80:1987;1029-1036.
7. Watkins P.B., Wrighton S.A., Maurel P.et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. U.S.A. 82:1985;6310-6314.
8. Wrighton S.A., Ring B.J., Watkins P.B., Vandenbranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 36:1989;97-105.
9. Watkins P.B., Murray S.A., Winkelman L.G., Heuman D.M., Wrighton S.A., Guzelian P.S. The erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J. Clin. Invest. 83:1989;688-697.
10. Kolars J.C., Schmiedlin-Ren P., Schuetz J., Ghosh M., Dobbins W.O., Watkins P.B. Expression of P450IIIA4 in duodenal mucosa: Interpatient variability and regulation in cultured explants. Gastroenterology. 100:1991;A221.
11. Kolars J.C., Schmiedlin-Ren P., Schuetz J.D., Fang C., Watkins P.B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90:1992;1871-1878.
12. Lown K.S., Kolars J.C., Thummel K.E.et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22:1994;947-955.
13. Watkins P.B. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol. Pharmacol. 21:1992;511-526.
14. Gomez D.Y., Wacher V.J., Tomlanovich S.J., Hebert M.F., Benet L.Z. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 58:1995;15-19.
15. Gupta S.K., Bakran A., Johnson R.W.G., Rowland M. Cyclosporin-erythromycin interaction in renal transplant patients. Br. J. Clin. Pharmacol. 27:1989;475-481.
16. Aoyama T., Yamano S., Waxman D.J.et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 264:1989;10388-10395.
17. Watkins P.B., Hamilton T.A., Annesley T.M., Ellis C.N., Kolars J.C., Voorhees J.J. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin. Pharmacol. Ther. 48:1990;120-129.
18. Turgeon D.K., Normolle D.P., Lerchman A.B., Annesley T.M., Smith D.E., Watkins P.B. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin. Pharmacol. Ther. 52:1992;471-478.
19. Kolars J.C., Merion R., Awni W.M., Watkins P.B. First pass metabolism of cyclosporin by the gut. Lancet. 338:1991;1488-1490.
20. Webber I.R., Peters W.H.M., Back D.J. Cyclosporine metabolism by human gastrointestinal mucosal microsomes. Br. J. Clin. Pharmacol. 33:1992;661-664.
21. Sattler M., Guengerich F.P., Yun C-H., Christians U., Sewing K.F. Cytochrome p-4503A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20:1992;753-761.
22. Lampen A., Christians U., Guengerich F.P.et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab. Dispos. 23:1995;1315-1324.
23. Lampen A., Christians U., Gonschior A.et al. Metabolism of the macrolide immunosuppressant tacrolimus by the pig gut mucosa in the Ussing chamber. Br. J. Pharmacol. 117:1996;1730-1734.
24. Roninson I.B., Chin J.E., Choi K.et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 83:1986;4538-4542.
25. Kartner N., Riordan J.R., Ling V. Cell surface p-glycoprotein is associated with multidrug resistance in mammalian cell lines. Science. 221:1983;1285-1288.
26. Pavelic Z.P., Reising J., Pavelic L., Kelley D.J., Stambrook P.J., Gluckman J.L. Detection of p-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch. Otolaryngol. Head Neck Surg. 119:1993;753-757.
27. Lown K.S., Fontana R.J., Schmiedlin-Ren P., Turgeon D.K., Watkins P.B. Interindividual variation in intestinal mdr1 expression: lack of short term diet effects. Gastroenterology. 108:1995;A737.
28. Lown K.S., Mayo R.R., Leichtman A.B.et al. Role of intestinal p-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cylcosporine. Clin. Pharmacol. Ther. 62:1997;1-13.
29. Tamai I., Safa A.R. Competitive interaction of cyclosporine with vinca alkaloid-binding site of p-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 265:1990;16509-16513.
30. Golberg H., Ling V., Wong P.Y., Skorecki K. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun. 152:1988;552-558.
31. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human p-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268:1993;6077-6080.
32. First M.R., Schroeder T.J., Weiskittel P., Myre S.A., Alexander J.W., Pesce A.J. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet. II:1989;1198-1201.
33. Fabre G., Julian B., Saint-Aubert B., Joyeux H., Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos. 21:1993;978-985.
34. Dodic N., Dumaitre B., Daugan A., Pianetti P. Synthesis and activity against multidrug resistance in Chinese hamster ovary cells of new acridone-4-carboxamides. J. Med. Chem. 38:1995;2418-2426.
35. Shapiro A.B., Ling V. Reconstitution of drug transport purified p-glycoprotein. J. Biol. Chem. 270:1995;16167-16175.
36. Wigler P.W., Patterson F.K. Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim. Biophys. Acta. 1189:1994;1-6.
37. Kroemer H.K., Gautier J.C., Beaune P., Henderson C., Wold C.R., Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;332-337.
38. 3H)vinblastine transport by isolated vesicles. Biochim. Biophys. Acta. 1061:1991;106-110.
39. Baranc'ik M., Polekov'a L., Mr'azov'a T., Breier A., Stankovicov's T., Slez'ak J. Reversal effects of several Ca(2+)-entry blockers, neuroleptics and local anaesthetics on p-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line. Drugs Exp. Clin. Res. 20:1994;13-18.
40. Muller C., Bailly J.D., Goubin F.et al. Verapamil decreases p-glycoprotein expression in multidrug-resistant human leukemic cell lines. Int. J. Cancer. 56:1994;749-754.
41. Kobayashi Y., Yamashiro T., Nagatake H.et al. Expression and function of multidrug resistance p-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52. Biochem. Pharmacol. 48:1994;1641-1646.
42. Miura T., Iwasaki M., Komori M.et al. Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics. J. Antimicrob. Chemother. 24:1989;551-559.
43. Wrighton S.A., Ring B.J. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm. Res. 11:1994;921-924.
44. Kronbach T., Mathys D., Umeno M., Gonzalez F.J., Meyer U.A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Pharmacology. 36:1989;89-96.
45. Jurima-Romet M., Crawford K., Cyr T., Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispos. 22:1994;849-857.
46. Watkins P.B., Wrighton S.A., Schuetz E.G., Maurel P., Guzelian P.S. Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J. Biol. Chem. 261:1986;6264-6271.
47. Wrighton S.A., Maurel P., Schuetz E.G., Watkins P.B., Young B., Guzelian P.S. Identification of the cytochrome p-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome p-450p. Biochemistry. 24:1985;2171-2178.
48. Gant T.W., O'Connor C.K., Corbitt R., Thorgeirsson U., Thorgeirsson S.S. In vivo induction of liver p-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol. 133:1995;269-276.
49. Labroo R.B., Thummel K.E., Kunze K.L., Podoll T., Trager W.F., Kharasch E.D. Catalytic role of cytochrome p450 3A4 in multiple pathways of alfentanil metabolism. Drug Metab. Dispos. 23:1995;490-496.
50. Siegsmund M.J., Cardarelli C., Aksentijevich I., Sugimoto Y., Pastan I., Gottesman M.M. Ketoconazole effectively reverses multi-drug resistance in highly resistant KB cells. J. Urol. 151:1994;485-491.
51. Maurice M., Pichard L., Daujat M.et al. Effects of imidazole derivatives on cytochromes p450 from human hepatocytes in primary culture. FASEB J. 6:1992;752-758.
52. Prichard L., Fabre I., Fabre G.et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome p-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18:1990;595-606.
53. Kurosawa M., Okabe M., Hara N.et al. Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Ann. Hematol. 72:1996;17-21.
54. Manke A., Roos P.H., Hanstein W.G., Chabot G.G. In vivo induction of cytochrome P450 CYP3A expression in rat leukocytes using various inducers. Biochem. Pharmacol. 51:1996;1579-1582.
55. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of p-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:1996;311-318.
56. Edwards D.J., Bernier S.M. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci. 59:1996;1025-1030.
57. Miniscalco A., Lundahl J., Regardh C.G., Edgar B., Eriksson U.G. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharmacol. Exp. Ther. 261:1992;1195-1199.
58. Hardwick J.P., Gonzalez F.J., Kasper C.B. Transcriptional regulation of rat liver epoxide hydratase, NADPH-cytochrome P-450 oxidoreductase, and cytochrome P-450b genes by phenobarbital. J. Biol. Chem. 258:1983;8081-8085.
59. Simmons D.L., McQuiddy P., Kasper C.B. Induction of the hepatic mixed-function oxidase system by synthetic glucocorticoids. Transcriptional and post-transcriptional regulation. J. Biol. Chem. 262:1987;326-332.
60. Miguet J.P., Mavier P., Soussy C.J., Dhumeaux D. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology. 72:1977;924-926.
61. Fardel O., Lecureur V., Loyer P., Guillouzo A. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem. Pharmacol. 49:1995;1255-1260.
62. Murayama N., Shimada M., Yamazoe Y.et al. Distinct effects of phenobarbital and its N-methylated derivative on liver cytochrome p450 induction. Arch. Biochem. Biophys. 328:1996;184-192.
63. Thummel K.E., Shen D.D., Podoll T.D.et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. 271:1994;557-566.
64. Shaw P.M., Barnes T.S., Cameron D.et al. Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism. Biochem. J. 263:1989;653-663.
65. Donato M.T., Castell J.V., Gomez-Lechon M.J. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab. Dispos. 23:1995;553-558.
66. Schuetz E.G., Schuetz J.D., Strom S.C.et al. Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology. 18:1993;1254-1262.
67. Nicolau D.P., Uber W.E., Crumbley A.J., Strange C. Amiodarone-cyclosporine interaction in heart transplant patient. J. Heart Lung Transplant. 11:1992;564-568.
68. Chitwood K.K., Abdul-Haqq A.J., Heim-Duthoy K.L. Cyclosporine-amiodarone interaction. Ann. Pharmacother. 27:1993;569-571.
69. Mamprin F., Mullins P., Graham T.et al. Amiodarone-cyclosporine interaction in cardiac transplantation. Am. Heart J. 123:1992;1725-1726.
70. Morgenstern G.R., Powles R., Robinson B., McElwain T.J. Cyclosporine interaction with ketoconazole and melphalan. Lancet. 2:1982;1342.
71. Ferguson R.M., Sutherland D.E.R., Simmons R.L., Najarian J.S. Ketoconazole, cyclosporin metabolism and renal transplantation. Lancet. 2:1982;882-883.
72. Sorenson A.L., Lovdahl M., Hewitt J.M.et al. The effect of ketoconazole on cyclosporine metabolism in renal allograft recipients. Transplant. Proc. 26:1994;2822.
73. First M.R., Schroeder T.J., Michael A., Hariharan S., Weiskettel P., Alexander J.W. Cyclosporine-ketoconazole interaction. Transplantation. 55:1993;1000-1004.
74. First M.R., Schroeder T.J., Alexander J.W.et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation. 51:1991;365-370.
75. Trenk D., Brett W., Jahnchen E., Birnbaum D. Time course of cyclosporin/itraconazole interaction. Lancet. 2:1987;1335-1336.
76. Kwan J.T.C., Foxall P.J.D., Davidson D.G.C., Bending M.R., Eisinger A.J. Interaction of cyclosporin and itraconazole. Lancet. 2:1987;282.
77. Kramer M.R., Marshall S.E., Denning D.W.et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann. Intern. Med. 113:1990;327-329.
78. Lopez-Gil J.A. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann. Pharmacother. 27:1993;427-430.
79. Sugar A.M., Saunders C., Idelson B.A., Bernard D.B. Interaction of fluconazole and cyclosporine. Ann. Intern. Med. 110:1989;844.
80. Graves N.M., Matas A.J., Hilligoss D.M., Canafax D.M. Fluconazole/cyclosporine interaction. Clin. Pharmacol. Ther. 43:1990;208.
81. Collignon P., Hurley B., Mitchell D. Interaction of fluconazole with cyclosporin. Lancet. 1:1989;1262.
82. Neumayer H.H., Wagner K. Diltiazem and economic use of cyclosporin. Lancet. 2:1986;523.
83. Grino J.M., Sabate I., Castelao A.M., Alsina J. Influence of diltiazem on cyclosporin clearance. Lancet. 1:1986;1387.
84. Pochet J.M., Pirson Y. Cyclosporin-diltiazem interaction. Lancet. 1:1986;979.
85. Valantine H., Keogh A., McIntosh N., Hunt S., Oyer P., Schroeder J. Cost containment: coadministration of diltiazem with cyclosporine after heart transplantation. J. Heart Lung Transplant. 11:1992;1-8.
86. Sketris I.S., Methot M.E., Nicol D., Belitsky P., Knox M.G. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Ann. Pharmacother. 28:1994;1227-1231.
87. Lindholm A., Henricsson S. Verapamil inhibits cyclosporin metabolism. Lancet. 1:1987;1262-1263.
88. Tortorice K.L., Heim-Duthoy K.L., Awni W.M., Rao K.L., Kasiske B.L. The effect of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. Ther. Drug Monit. 12:1990;321-328.
89. Bourbigot B., Guiserix J., Airiau J., Bressollette L., Morin J.F., Cledes J. Nicardipine increases cyclosporin blood levels. Lancet. 1:1986;1447.
90. Klintmalm G., Sawe J. High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients. Lancet. 1:1984;731.
91. Gersema L.M., Porter C.B., Russell E.H. Suspected drug interaction between cyclosporine and clarithromycin. J. Heart Lung Transplant. 13:1994;343-345.
92. Ferrari S.L., Goffin E., Mourad M., Wallemacq P., Squifflet J.P., Pirson Y. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation. 58:1994;725-727.
93. Hourmant M., LeBigot J.F., Vernillet L., Sagniez G., Remi J.P., Soulillou J.P. Coadministration of erythromycin results in an increase of blood cyclosporine to toxic levels. Transplant. Proc. 17:1985;2723-2727.
94. Ptachinski R.J., Carpenter B.J., Burckart G.J., Venkataramanan R., Rosenthal J.T. Effect of erythromycin on cyclosporine levels. N. Engl. J. Med. 313:1985;1416-1417.
95. Grino J.M., Sabate I., Castelao A.M., Guardia M., Seron D., Alsina J. Erythromycin and cyclosporine. Ann. Intern. Med. 105:1986;467-468.
96. Godin J.R.P., Sketris I.S., Belitsky P. Erythromycin-cyclosporine interaction. Drug Intell. Clin. Pharm. 20:1986;504-505.
97. Kessler M., Louis J., Renoult E., Vigneron B., Netter P. Interaction between cyclosporin and erythromycin in a kidney transplant patient. Eur. J. Clin. Pharmacol. 30:1986;633-634.
98. Kohan D.E. Possible interaction between cyclosporine and erythromycin. N. Engl. J. Med. 314:1986;448.
99. Freeman D.J., Martell R., Carruthers S.G., Heinrich S.D., Keown P.A., Stiller C.R. Cyclosporin-erythromycin interaction in normal subjects. Br. J. Clin. Pharmacol. 23:1987;776-778.
100. Wadhwa N.K., Schroeder T.J., O'Flaherty E.et al. Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient. Ther. Drug Monit. 9:1987;123-125.
101. Jensen C.W.B., Flechner S.M., Van Buren C.T.et al. Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. Transplantation. 43:1987;263-270.
102. Harnett J.D., Parfrey P.S., Paul M.D., Gault M.H. Erythromycin-cyclosporine interaction in renal transplant recipients. Transplantation. 43:1987;316-318.
103. Zylber-Katz E. Multiple drug interactions with cyclosporine in a heart transplant patient. Ann. Pharmacother. 29:1995;127-131.
104. Ducharme M.P., Warbasse L.H., Edwards D.J. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 57:1995;485-491.
105. Wadhwa N.K., Schroeder T.J., O'Flaherty E., Pesce A.J., Myre S.A., First M.R. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation. 43:1987;211-213.
106. Chang T., Benet L.Z., Hebert M.F. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 59:1996;297-303.
107. Deray G., LeHoans P., Cacoub P., Assogba U., Grippon P., Baumelou A. Oral contraceptive interaction with cyclosporin. Lancet. 1:1987;158-159.
108. Ross W.B., Roberts D., Griffin P.J.A., Salaman J.R. Cyclosporin interaction with danazol and norethisterone. Lancet. 1:1986;330.
109. Endresen L., Bergan S., Holdaas H., Pran T., Sinding-Larsen B., Berg K.J. Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. Ther. Drug Monit. 13:1991;490-495.
110. Henricsson S., Lindholm H. Inhibition of cyclosporine metabolism by other drugs in vitro. Transplant. Proc. 20:1988;569-571.
111. Tjia J.F., Back D.J., Breckenridge A.M. Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes. Br. J. Clin. Pharmacol. 28:1989;362-365.
112. Wagner K., Philipp Th., Heinemeyer G.et al. Interaction of cyclosporine and calcium antagonists. Transplant. Proc. 21:1989;1453-1456.
113. Christians U., Bleck J.S., Lampen A.et al. Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem? Transplant. Proc. 28:1996;2159-2161.
114. Cooney G.F., Mochon M., Kaiser B., Dunn S.P., Goldsmith B. Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. Pharmacotherapy. 15:1995;353-356.
115. Carstensen H., Jacobsen N., Dieperink H. Interaction between cyclosporin A and phenobarbitone. Br. J. Clin. Pharmacol. 21:1986;550-551.
116. Freeman D.J., Laupacis A., Keown P.A., Stiller C.R., Carruthers S.G. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br. J. Clin. Pharmacol. 18:1984;887-893.
117. Keown P.A., Laupacis A., Carruthers G.et al. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation. 38:1984;304-306.
118. Van Buren D., Wideman C.A., Ried M.et al. The antagonistic effect of rifampin upon cyclosporine bioavailability. Transplant. Proc. 16:1984;1642-1645.
119. Modry D.L., Stinson E.B., Oyer P.E., Jamieson S.W., Baldwin J.C., Shumway N.E. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation. 39:1985;313-314.
120. Offermann G., Keller F., Molzahn M. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am. J. Nephrol. 5:1985;385-387.
121. Vandevelde C., Chang A., Andrews D., Riggs W., Jewesson P. Rifampin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy. 11:1991;88-89.
122. Cassidy M.J.D., Van Zyl-Smit R., Pascoe M.D., Swanepoel C.R., Jacobson J.E. Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient. Nephron. 41:1985;207-208.
123. Langhoff E., Madsen S. Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment. Lancet. 2:1983;1031.
124. Jones D.K., Hakim M., Wallwork J., Higenbottam T.W., White D.J.G. Serious interaction between cyclosporine A and sulphadimidine. Br. Med. J. 292:1986;728-729.
125. Osowski C.L., Dix S.P., Lin L.S., Mullins R.E., Geller R.B., Wingard J.R. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation. 61:1996;1268-1272.
126. Mieles L., Venkataramanan R., Yokoyama I., Warty V.J., Starzl T.E. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation. 52:1991;1086-1087.
127. Shapiro R., Venkataramanan R., Warty V.S.et al. FK 506 interaction with danazol. Lancet. 341:1993;1344-1345.
128. Shaeffer M.S., Collier D., Sorrell M.F. Interaction between FK506 and erythromycin. Ann. Pharmacother. 28:1994;280-281.
129. Jensen C., Jordan M., Shapiro R.et al. Interaction between tacrolimus and erythromycin. Lancet. 344:1994;825.
130. Furlan V., Perello L., Jacquemin E., Debray D., Taburet A.M. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation. 59:1995;1217-1218.
131. Iwasaki K., Matuda H., Nagase K., Shiraga T., Tokuma Y., Uchida K. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res. Commun. Chem. Pathol. Pharmacol. 82:1993;209-216.